Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marcio Fagundes

Radiation Oncology Miami, FL Medical Doctor

NPI 1063604692 CMS profile 229863

8900 N Kendall Dr, Miami Cancer Institute, Miami, FL 33176

Open in the dashboard

General payments

$273,887

227 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marcio Fagundes of Miami, FL is reported in the CMS Open Payments database as having received $273,887 across 227 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Radiation Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33,644 24
2024 General $9,130 19
2023 General $38,930 38
2022 General $83,537 59
2021 General $39,514 36
2020 General $38,493 26
2019 General $30,640 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marcio Fagundes
  • Radiation Oncology median
  • Middle half of Radiation Oncology
  • National median

In program year 2025, general payments to Marcio Fagundes were reported at $33,644. Among 3,409 Radiation Oncology profiles paid that year, the median was $172 and the middle half received between $61 and $514.

Show as a table
Year Marcio Fagundes Radiation Oncology median Middle half National median
2019 $30,640 $138 $48–$462 $163
2020 $38,493 $79 $26–$262 $114
2021 $39,514 $119 $37–$358 $132
2022 $83,537 $139 $43–$424 $149
2023 $38,930 $167 $57–$473 $160
2024 $9,130 $168 $56–$541 $164
2025 $33,644 $172 $61–$514 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $235,122 200 payments
  2. Augmenix, Inc. $20,873 6 payments
  3. Palette Life Sciences, Inc. $13,276 5 payments
  4. Bioprotect Medical, Inc. $1,798 7 payments
  5. Ion Beam Applications S.A. $1,343 2 payments
  6. Qfix $1,000 1 payment
  7. Pfizer Inc. $277 2 payments
  8. IBA Proton Therapy, Inc. $108 1 payment
  9. Siemens Medical Solutions USA, Inc. $64 2 payments
  10. Accuray Incorporated $26 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $137,288 76 payments
  2. Consulting Fee $109,081 48 payments
  3. Travel and Lodging $19,963 26 payments
  4. Food and Beverage $6,555 76 payments
  5. Honoraria $1,000 1 payment
Products named General payments · program years 2019–2025
  1. SpaceOAR System $48,709 39 payments
  2. General - Therapies $48,355 21 payments
  3. SPACEOAR VUE $39,364 33 payments
  4. SpaceOAR VUE System - 10mL SpaceOAR VUE_URO $34,524 52 payments
  5. GENERAL - BPH $27,721 10 payments
  6. SpaceOAR Oncology $20,873 6 payments
  7. SpaceOAR VUE System - 10mL Bph $15,225 5 payments
  8. SPACEOAR Bph $10,623 18 payments
  9. General BPH $6,232 8 payments
  10. BIOPROTECT BALLOON IMPLANT SYSTEM $1,798 7 payments
  11. Other $2,537 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$136,951

Medicare's payments for the services billed

Medicare patients

321

Average age 76

Services billed

1,915

93 women, 228 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 75%
Arthritis 46%
Ischemic heart disease 45%
Diabetes 36%
Chronic kidney disease 23%
COPD 20%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

227 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Radiation Oncology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record